Update on childhood and adolescent immunizations: Selected review of US recommendations and literature: Part 1

Current Opinion in Pediatrics

Volumn 23, Issue 4, 2011, Pages 460-469

  Fay, Kathryn E ^a   Lai, Joanne ^b   Bocchini, Joseph A ^c  

^a CHILDREN S HOSPITAL AT DARTMOUTH   (United States)

^b North Shore Long Island Jewish Health System ^*  (United States)

^c Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

immunization; vaccine; vaccine effectiveness; vaccine safety

Indexed keywords

HAEMOPHILUS INFLUENZAE VACCINE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; PCV13; PCV7; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; RV1; UNCLASSIFIED DRUG;

ACUTE GASTROENTERITIS; ADOLESCENT; ADOLESCENT HEALTH; ANTIBODY DETECTION; AWARENESS; BACTERIAL STRAIN; CHILD; CHILD HEALTH; CLINICAL PRACTICE; DELTOID MUSCLE; HAEMOPHILUS INFLUENZAE TYPE B; HEALTH PROMOTION; HEPATITIS B; HIGH RISK PATIENT; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNIZATION; INFLUENZA; MEDICAL RECORD REVIEW; NATIONAL HEALTH ORGANIZATION; OBESITY; OTITIS MEDIA; PEDIATRICS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; ROTAVIRUS INFECTION; SEROTYPE; SINUSITIS; STREPTOCOCCUS PNEUMONIAE; VACCINE FAILURE; VIRUS DETECTION; WELLBEING;

ADOLESCENT; BACTERIAL VACCINES; CHILD; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B; HUMANS; IMMUNIZATION SCHEDULE; PNEUMOCOCCAL INFECTIONS; ROTAVIRUS INFECTIONS; UNITED STATES; VACCINATION; VIRAL VACCINES;

EID: 79960772035     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32834877f1     Document Type: Review

References (41)

1. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Part 1: Immunization of infants, children and adolescents. MMWR 2005; 54:1-23.
2. Armstrong GL, Mast EE, Wojczynski M, Margolis HS. Childhood hepatitis B virus infections in the United States before hepatitis B immunization. Pediatrics 2001; 108:1123-1128. (Pubitemid 33021186)
3. Wasley A, Kruszon-Moran D, Kuhnert W, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 2010; 202:192-201.
4. Zhang L, Xu A, Yan B, et al. A significant reduction in hepatitis B infection among the children of Shandong Province, China: the effect of 15 years of universal infant hepatitis B vaccination. Int J Infect Dis 2010; 14:e483-e488.
5. Roznovsky L, Orsagova I, Kloudova A, et al. Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up. Infection 2010; 38:395-400.
6. Poorolajal J, Mahmoodi M, Haghdoost A, et al. Booster dose vaccination for preventing hepatitis B. Cochrane Database Syst Rev 2010; CD008256.
7. Middleman AB, Anding R, Tung C. Effect of needle length when immunizing obese adolescents with hepatitis B vaccine. Pediatrics 2010; 125:e508-e512.
8. Desai SN, Esposito DB, Shapiro ED, et al. Effectiveness of rotavirus vaccine in preventing hospitalization due to rotavirus gastroenteritis in young children in Connecticut, USA. Vaccine 2010; 28:7501-7506.
9. Boom JA, Tate JE, Sahni LC, et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 2010; 125:e199-e207.
10. Boom JA, Tate JE, Sahni LC, et al. Sustained protection from pentavalent rotavirus vaccination during the second year of life at a large, urban United States pediatric hospital. Pediatr Infect Dis J 2010; 29:1133-1135.
11. Curns AT, Steiner CA, Barrett M, et al. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis 2010; 201:161 7-1624.
12. Cortese MM, Tate JE, Simonsen L, et al. Reduction in gastroenteritis in United States children and correlation with early rotavirus vaccine uptake from national medical claims databases. Pediatr Infect Dis J 2010; 29:489-494.
13. Begue RE, Perrin K. Reduction in gastroenteritis with the use of pentavalent rotavirus vaccine in a primary practice. Pediatrics 2010; 126:e40-e45.
14. Wang FT, Mast TC, Glass RJ, et al. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics 2010; 125:e208-e213.
15. Chang HH, Smith PF, Tserenpuntsag B, et al. Reduction in hospitalizations for diarrhea and rotavirus infections in New York State following introduction of rotavirus vaccine. Vaccine 2010; 28:754-758.
16. Yen C, Steiner CA, Barrett M, et al. Racial disparities in diarrhea-associated hospitalizations among children in five US states before and after introduction of rotavirus vaccine. Vaccine 2010; 28:7423-7426.
17. Field EJ, Vally H, Grimwood K, et al. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics 2010; 126:e506-e512.
18. Ruiz-Palacios GM, Perez Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22. (Pubitemid 43048947)
19. Muhsen K, Chodick G, Goren S, et al. The uptake of rotavirus vaccine and its effectiveness in preventing gastroenteritis in the community. Vaccine 2011; 29:91-94.
20. Belongia EA, Irving SA, Shui IM, et al. Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. Pediatr Infect Dis J 2010; 29:1-5.
21. Patel NC, Hertel PM, Estes MK, et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med 2010; 362: 314-319.
22. Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older, recommendations of the ACIP. MMWR 1991; 40:1-7.
23. Centers for Disease Control and Prevention. Updated recommendations for use of Haemophilus influenzae type b (Hib) vaccine: reinstatement of the booster dose at ages 12-15 months. MMWR 2009; 58:673-674.
24. Huang WT, Chang S, Miller ER, et al. Safety assessment of recalled Haemophilus influenzae type b (Hib) conjugate vaccines - United States 2007-2008. Pharmacoepidemiol Drug Saf 2010; 19:306-310.
25. Kempe A, Babbel C, Wallace GS, et al. Knowledge of interim recommendations and use of Hib vaccine during vaccine shortages. Pediatrics 2010; 125:914-920.
26. Hallander HO, Lepp T, Ljungman M, et al. Do we need a booster of Hib vaccine after primary vaccination? A study on anti-Hib seroprevalence in Sweden 5 and 15 years after the introduction of universal Hib vaccination related to notifications of invasive disease. Acta Pathol Microbiol Immunol Scand 2010; 118:878-887.
27. Ladhani S, Heath PT, Aibara RJ, et al. Long-term complications and risk of other serious infections following invasive Haemophilus influenzae serotype b disease in vaccinated children. Vaccine 2010; 28:2195-2200.
28. Ladhani S, Borrow R, Heath PT, et al. Low serum serotype-specific pneumococcal antibody concentrations in young children with Haemophilus influenzae serotype b (Hib) vaccine failure. Vaccine 2010; 28:4440-4444.
29. Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP). MMWR 2010; 59:258-261.
30. Nuorti JP, Whitney CG. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. MMWR 2010; 59:1-18.
31. Yildirim I, Hanage WP, Lipsitch M, et al. Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine 2011; 29:283-288.
32. Casey JR, Adlowitz DG, Pichichero ME. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumo-coccal conjugate vaccine. Pediatr Infect Dis J 2010; 29:304-309.
33. Van Gils EJM, Veenhoven RH, Hak E, et al. Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains. JAMA 2010; 304:1099-1106.
34. Millar EV, Pimenta FC, Roundtree A, et al. Pre and postconjugate vaccine epidemiology of pneumococcal serotype 6C invasive disease and carriage within Navajo and White Mountain Apache communities. Clin Infect Dis 2010; 51:1250-1265.
35. Dupont D, Mahjoub-Messai F, Francois M, et al. Evolving microbiology of complicated acute otitis media before and after introduction of the pneumococcal conjugate vaccine in France. Diagn Microbiol Infect Dis 2010; 68:89-92.
36. Bender JM, Ampofo K, Byington CL, et al. Epidemiology of Streptococcus pneumoniae-induced hemolytic uremic syndrome in Utah children. Pediatr Infect Dis J 2010; 20:712-716.
37. Lucero MG, Dulalia VE, Nillos LT, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009; CD004977.
38. Dagan R, Givon-Lavi N, Greenberg D, et al. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J Infect Dis 2010; 201:1570-1579.
39. Vakevainen M, Soininen A, Lucero M, et al. Serotype-specific hypo-responsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination. J Pediatr2010; 157:778-783.
40. Bryant KA, Block SL, Baker SA, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics 2010; 125:866-875.
41. Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vacc Immunol 2010; 17:1017-1026.